



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY ¹

Last Trade:	69.97
Trade Time:	4:00 PM ET 05.24.2017
Change:	-4.90 (6.545%)
Day Range	67.34 - 71.48
52-Week Range	31.38 - 80.11
Volume	4,762,614
Market Cap. (\$M)	6,030.714
Shares Out (M)	86.190

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 05.24.2017
[Alnylam Pharmaceuticals Prices Public Offering of Common Stock](#)
- 05.23.2017
[Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock](#)
- 05.12.2017
[Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Financial Officer](#)
- 05.10.2017
[Alnylam to Webcast Presentations at Upcoming May Investor Conferences](#)
- 05.09.2017
[Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- 02.15.2017
[Annual Report \(10-K\)](#)
- 03.17.2017
[Definitive Proxy Statement](#)
- 05.05.2017
[Quarterly Report \(10-Q\)](#)
- 11.03.2016
[Quarterly Report \(10-Q\)](#)
- 08.04.2016
[Quarterly Report \(10-Q\)](#)